Bill Gillette
One doctor's opinion: BPCA should require publishing of studies
Physicians continue to prescribe imiquimod for children with molluscum contagiosum though study findings don't support efficacy and safety. One doctor calls for a shift in practice.
New antibiotic may prove useful in treating acne, MRSA infections
Findings could pave the way to more effective treatments for drug-resistant infections caused by MRSA
Final trial phase begins for drug’s plaque-psoriasis indication
Final trial phase begins for drug’s plaque-psoriasis indication
A phase 3 clinical program is under way to further evaluate the efficacy and safety of Cimzia (certolizumab pegol, UCB) in adult patients with moderate to severe chronic plaque psoriasis.
International study reveals benefits of lower-body liposculpting
An international research team looks at the data and advances their body contouring theory.
Chinese, Aussies differ in their views of cosmetic procedures
Where does cosmetic surgery rank when it comes to improving appearance? Two different countries; two different opinions.
LEO seeks FDA approval for aerosol-foam psoriasis treatment
LEO Pharma has submitted a new drug application to the FDA for calcipotriene and betamethasone dipropionate aerosol foam for the treatment of plaque psoriasis. Read to learn more.
Early results show promise for Kaposi’s Sarcoma drug
A Los Angeles-based biopharmaceutical research and development firm, has released interim results of its phase 2 clinical trial. Read to learn more.
Gel/antibiotic combo rivals ISO in treating severe acne
A Canadian study suggests that Epiduo Gel used in combination with the oral antibiotic doxycycline, compares favorably with oral isotretinoin in the treatment of severe nodular acne. Learn more
Human collagen composite compared against commercial fillers
A team of Korean researchers working to advance dermal fillers compare the biocompatibility and durability found in commercially available fillers .
EB drug has significant medical, market potential
Scioderm Inc. has released data from its recently completed phase 2b clinical trial — and plans for a phase 3 trial — on its investigational therapy Zorblisa (SD-101), a topical treatment for blistering and lesions associated with epidermolysis bullosa (EB). Read to learn more


View Results